Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma-Reference-Cited by-同舟云学术

Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma

Published:2021-11-26 Issue: Volume: Page:
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Fedorova Liudmila V.^ORCID,Lepik Kirill V.,Volkov Nikita P.,Kotselyabina Polina V.,Borzenkova Evgenia S.,Popova Marina O.,Beynarovich Anastasia V.,Baykov Vadim V.,Kozlov Andrey V.,Moiseev Ivan S.,Mikhailova Natalia B.,Kulagin Alexander D.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s10147-021-02085-6.pdf

Reference43 articles.

1. National Cancer Institute Surveillance Epidemiology and End Results Program (2019). Cancer stat facts: Hodgkin lymphoma. SEER https://seer.cancer.gov/statfacts/html/hodg.html

2. Kuruvilla J, Keating A, Crump M (2011) How I treat relapsed and refractory Hodgkin lymphoma. Blood 117(16):4208–4217. https://doi.org/10.1182/blood-2010-09-288373

3. Armitage JO (2010) Early-stage Hodgkin’s lymphoma. N Engl J Med 363(7):653–662. https://doi.org/10.1056/NEJMra1003733

4. Kuruvilla J (2009) Standard therapy of advanced Hodgkin lymphoma. Hematol Am Soc Hematol Educ Program. https://doi.org/10.1182/asheducation-2009.1.497

5. Andre’ M, Henry-Amar M, Pico JL et al (1999) Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin’s disease induction failure: a case-control study. J Clin Oncol. https://doi.org/10.1200/JCO.1999.17.1.222

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. All-cause and immune checkpoint inhibitor–associated acute kidney injury in immune checkpoint inhibitor users: a meta-analysis of occurrence rate, risk factors and mortality;Clinical Kidney Journal;2023-11-28

2. Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma;Advances in Radiation Oncology;2023-11

3. The role of radiotherapy in patients with refractory Hodgkin's lymphoma after treatment with brentuximab vedotin and/or immune checkpoint inhibitors;Journal of the National Cancer Center;2023-11

4. Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up;Blood Advances;2023-09-13

5. Focused ultrasound-mediated small-molecule delivery to potentiate immune checkpoint blockade in solid tumors;Frontiers in Pharmacology;2023-04-26